



Accepted Article

Title: N-Sulfonyl-1,2,3,4-tetrahydroisoquinoline Derivatives: Synthesis, Antimicrobial Evaluations, and Theoretical Insights

Authors: Martín Rinaldi Tosi, Valeria Palermo, Fernando Giannini, Martín Fernández-Baldo, Jorge Diaz, Beatriz Lima, Gabriela Feresin, Guastavo Romanelli, and Héctor Armando Baldoni

This manuscript has been accepted after peer review and appears as an Accepted Article online prior to editing, proofing, and formal publication of the final Version of Record (VoR). The VoR will be published online in Early View as soon as possible and may be different to this Accepted Article as a result of editing. Readers should obtain the VoR from the journal website shown below when it is published to ensure accuracy of information. The authors are responsible for the content of this Accepted Article.

To be cited as: *Chem. Biodiversity* **2023**, e202300905

Link to VoR: <https://doi.org/10.1002/cbdv.202300905>

***N*-Sulfonyl-1,2,3,4-tetrahydroisoquinoline Derivatives: Synthesis, Antimicrobial Evaluations, and Theoretical Insights**

Martín E. Rinaldi Tosi,^[a] Valeria Palermo,^[b] Fernando A. Giannini,^[c] Martín A. Fernández Baldo,^[d] Jorge R. A. Díaz,^[c] Beatriz Lima,^[e] Gabriela E. Feresin,^[e] Gustavo P. Romanelli,^[b,f] and Héctor A. Baldoni*^[c,g]

[a] Dr. Martín E. Rinaldi Tosi⁺

Laboratorio de Biotecnología y Tecnologías Biomédicas, Centro de Estudios para la Innovación y el Desarrollo (CEPID), Facultad de Ciencias Médicas, Universidad Católica de Cuyo, Felipe Velázquez 471 CP: 5700 Ciudad de San Luis, Argentina.

[b] Dra. Valeria Palermo⁺, Dr. Gustavo P. Romanelli

Grupo de Investigación en Síntesis Orgánica Ecoeficiente (GISOE), Centro de Investigación y Desarrollo en Ciencias Aplicadas ‘Dr. Jorge J. Ronco’ (CINDECA), Departamento de Química, Facultad de Ciencias Exactas, Universidad Nacional de La Plata – CIC – CONICET, Calle 47 Nro 257, B1900AJK La Plata, Argentina.

[c] Dr. Fernando A. Giannini, Dr. Jorge R. A. Díaz

Área de Química General e Inorgánica, Departamento de Química, Facultad de Química, Bioquímica y Farmacia, Universidad Nacional de San Luis, Chacabuco 917, D5700BWS San Luis, Argentina.

[d] Dr. Martín A. Fernández Baldo

Universidad Nacional de San Luis, Facultad de Química, Bioquímica y Farmacia, Área de Química Analítica - Instituto de Química de San Luis, INQUISAL (UNSL – CONICET), Chacabuco 917, D5700BWS San Luis, Argentina.

[e] Dra. Beatriz Lima; Dra. Gabriela E. Feresin

Instituto de Biotecnología, Instituto de Ciencias Básicas, Universidad Nacional de San Juan, Av. Libertador General San Martín 1109 O, San Juan, Argentina.

[f] Dr. Gustavo P. Romanelli

CISAV. Cátedra de Química Orgánica, Facultad de Ciencias Agrarias y Forestales, Universidad Nacional de La Plata, Calles 60 y 119 s/n, B1904AAN La Plata, Argentina.

[g] Dr. Héctor A. Baldoni*

Instituto de Matemática Aplicada de San Luis, IMASL (UNSL – CONICET), Av. Italia 17556, D5700BYO San Luis, Argentina, <http://www.unsl.edu.ar>, E-mail:

hbaldoni@unsl.edu.ar

1 Abstract

2 Microbial contamination remains a significant economic challenge in the food
3 industry, emphasizing the need for innovative antimicrobial solutions. In this study, we
4 synthesized *N*-sulphonyl-1,2,3,4-tetrahydroisoquinolines (NSTHIQ) derivatives using an
5 environmentally friendly Preyssler heteropolyacid catalyst, obtaining moderate to high
6 yields (35-91%) under mild conditions. Two derivatives (**5** and **6**) exhibited significant
7 antifungal properties against various fungal species, including *Aspergillus spp*, *Penicillium*
8 *spp*, and *Botrytis cinerea*. ADMET (Absorption, Distribution, Metabolism, Excretion, and
9 Toxicity) analysis revealed the absence of hepatic toxicity in all compounds, making
10 derivatives **2**, **3**, **4**, and **5** potential candidates for further development. However,
11 derivatives **6** and **7** exhibited immunotoxicity. In support of our experimental findings,
12 reactivity indices were computed using Density Functional Theory principles, deriving
13 valuable insights into the chemical properties of these derivatives. This study underscores
14 the potential of NSTHIQ compounds as potent antifungal agents, coupled with the
15 importance of employing environmentally friendly catalysts in drug discovery.

16

17 Introduction

18 Food loss and waste resulting from chemical or biological contamination pose a
19 significant global food challenge, impacting not only the source materials but also the
20 derived products. While chemical contamination risks are more prominent in
21 conventionally farmed products, organic farming carries a higher likelihood of biological
22 contamination. Furthermore, food degradation caused by contamination from various
23 microorganisms is the leading cause of economic losses within the food supply chain. This
24 issue primarily affects the post-harvest phase and has repercussions throughout the entire
25 food production chain, encompassing farmers, warehouse operators, sellers, and consumers

1 at different stages, including production and pre-harvest, harvesting and initial handling,
2 storage, transportation, processing, retail, and consumption. According to the Food and
3 Agriculture Organization (FAO), the matter of food security holds implications not only
4 for public health but also for government oversight and regulatory agencies.^[1]

5 Phytopathogenic fungi can colonize crops and generate mycotoxins within the edible
6 parts of plants. These mycotoxins can accumulate in infected food products, posing a
7 significant risk to both human and animal health. When these mycotoxins come into
8 contact with or are ingested by individuals, they can have adverse effects on their health.
9 As a result, these fungi and the toxins they produce are responsible for numerous cases of
10 mycotoxicosis. Furthermore, these mycotoxins have been identified as carcinogens that
11 promote the development of tumours, particularly hepatocarcinoma, and they also exhibit
12 strong allergenic properties.^[2]

13 Various fungi are known to cause postharvest diseases in food crops. Notably,
14 *Aspergillus spp.* and *Penicillium spp.* are two prominent genera in this regard. While these
15 fungi are commonly found in soil and air and are generally considered saprophytic, some
16 species within these genera can cause deterioration during food storage, plant diseases, or
17 even invasive diseases in animals and humans. *Alternaria spp.* are primarily saprophytic
18 fungi, but certain species have developed pathogenic capabilities, collectively causing
19 diseases across a wide range of hosts. *Botrytis cinerea* often referred to as "grey mold,"
20 produces various toxins and possesses virulence factors that lead to rapid plant tissue death
21 and decomposition. Lastly, *Fusarium spp.* constitutes a genus of filamentous fungi with
22 considerable agricultural importance. They are known for being plant pathogens, producers
23 of mycotoxins, and opportunistic human pathogens. These genera were selected for their
24 global significance from both biochemical and economic perspectives and represent some
25 of the most common culprits associated with food spoilage and mycotoxin production.^[3]

1 The control of these postharvest diseases primarily relies on agricultural pesticides.
2 Nevertheless, the ongoing application of these substances has led to growing resistance in
3 fungal populations, making eradication increasingly challenging. In light of this situation,
4 there is a global drive to identify novel antimicrobial agents that exhibit enhanced efficacy,
5 particularly against microbial strains that have developed resistance to all presently known
6 antimicrobial agents.^[4]

7 Therefore, it is imperative to develop novel antifungal agents and improve existing
8 ones for the benefit of both agriculture and human health. Nevertheless, the concurrent
9 increase in antimicrobial drug resistance, exacerbated by the indiscriminate use of
10 antimycotic treatments, underscores the urgent necessity for a broader range of
11 medications to effectively combat fungal infections.

12 *N*-sulphonyl-1,2,3,4-tetrahydroisoquinoline (NSTHIQ) derivatives represent a
13 common structural element found in a diverse array of biologically active natural
14 compounds and pharmaceutical substances. Furthermore, their utility in treating various
15 diseases, such as Parkinson's, leukaemia, Alzheimer's, acquired immunodeficiency
16 syndrome (AIDS), and melanoma, has been documented.^[5]

17 On the other hand, sulfonamide groups are widely recognized for their diverse
18 biological properties, which encompass anticancer, antiviral, antibacterial,
19 antihypertensive, and antiepileptic effects.^[6] The NSTHIQ derivatives, which combine
20 isoquinolines and sulfonamides, have demonstrated their utility in various medical
21 applications, and numerous biologically active compounds featuring this substructure
22 exhibit a wide range of pharmacological effects.^[5,6]

23 The traditional synthesis of NSTHIQ derivatives involves the Pictet-Spengler
24 reaction. This process includes the condensation of *N*-sulphonyl-phenylethylamine with a
25 carbonyl compound, followed by an intramolecular aromatic electrophilic substitution.^[7]

1 This reaction typically occurs in a strong acid environment or supported Wells-Dawson,
2 Preyssler, and Keggin heteropolyacids.^[8,9]

3 Preyssler heteropolyacids are characterized by the general formula
4 $H_xA_y[B_5D_{30}O_{110}] \cdot zH_2O$, where x, y, and z fall within the following ranges: $0 < x < 15$,
5 $0 < y < 15$, and $0 < z < 50$. These compounds feature a cyclic structure that originates from the
6 Keggin anion ($BD_{12}O_{40}^{3-}$) through the removal of two sets of three corner-sharing DO_6
7 octahedra. Some examples within this family include $H_{14}NaP_5W_{30}O_{110}$ and
8 $H_{14}NaP_5W_{29}MoO_{110}$ (PwMo).^[10,11] Preyssler heteropolyacids serve as efficient and
9 environmentally friendly catalysts due to their strong Brønsted acidity, hydrolytic stability,
10 low corrosiveness, ease of recovery, and minimal waste production. They have a wide
11 range of applications, including catalyzing the selective oxidation of alcohols and
12 aldehydes, ammoxidation of 2-methylpyrazine, aerobic oxidation of H_2S , esterification of
13 alcohols, etherification of hydroxymethylfurfural, and facilitating the synthesis of diverse
14 heterocycles through multicomponent reactions, such as phenylcoumarins and pyrroles,
15 among others reactions.^[10,12]

16 In this study, was utilized a Preyssler bulk solid, specifically PwMo, as an
17 environmentally friendly and recyclable catalyst for synthesizing NSTHIQ derivatives.
18 These newly synthesized compounds were assayed for their potential antifungal properties
19 against a range of *Aspergillus* species (*A. niger*, *A. flavus*, *A. parasiticus*, and *A.*
20 *ochraceus*), *Penicillium* species (*P. expansum* and *P. verrucosum*), *Alternaria* species (*A.*
21 *alternate* and *A. tenuissima*), *Botrytis cinerea*, and *Fusarium oxysporum*. Additionally, we
22 evaluated the compounds for their antibacterial activity against both Gram-positive
23 *Staphylococcus aureus* strains and Gram-negative *Escherichia coli* strains. Furthermore,
24 we conducted drug-likeness assessments based on Lipinski's "Rule of Five," examined
25 ADME (Absorption, Distribution, Metabolism, and Elimination) properties, assessed


1 toxicological risks, and calculated reactivity indices using theoretical Density Functional
2 Theory (DFT).

3

4 Results and Discussion

5 Chemistry

6 All derivatives included in this study are known and they were resynthesized,
7 purified, and characterized to evaluate the biological activity.^[12] The synthetic route to
8 obtain the NSTHIQ derivatives **2** to **7** is shown in *Scheme 1*. The synthesis was
9 accomplished in high yield by a Preyssler bulk solid PWMo as a green recyclable catalyst.
10



14

12 **Scheme 1.** Synthesis of the NSTHIQ derivatives **2** to **7**. [a] Unless otherwise mentioned,
13 reaction was carried out with sulfonamide (1 mmol), trioxane (3 mmol), toluene (2 mL), catalyst
14 PWMo 1%mmol, at 70°C, 30 min., and stirring.

15

16 All synthesized compounds were insoluble in water but soluble in organic solvents
17 like *N,N*-dimethylformamide (DMF) and dimethylsulfoxide (DMSO). The synthesized
18 compounds were off-white solids with relatively high melting points. The structures of

6

1 them (*Scheme 1*) were determined and characterized by different experimental
2 spectroscopic techniques such as $^1\text{H-NMR}$, $^{13}\text{C-NMR}$, and MS. For spectral data, and
3 spectra, please see the *Supporting Information*. In addition, theoretical computation of $^1\text{H-}$
4 and $^{13}\text{C-NMR}$ signal assignments are accompanying the experimental data.^[13] This
5 comparison is not only to make the entire signals assignment straightforward but also to
6 guarantee unbiased experimental information. It is noteworthy that a remarkable
7 concordance exists when comparing the experimental $^1\text{H-}$ and $^{13}\text{C-NMR}$ chemical shift
8 spectra with the calculated ones. The coefficient of determination (denoted as R^2) is
9 approximately 0.99 for both $^1\text{H-NMR}$ and $^{13}\text{C-NMR}$ chemical shifts in their respective
10 datasets, as shown in *Figure S1*. Indeed, it is important to highlight that experimental
11 results stem from overlapping spectra of low-energy conformers of the compounds in
12 solution. Conversely, for the theoretical spectrum calculations, we adopted a gauche
13 conformation for the sulfonamide $\text{C}^1\text{-N-S-R}$ rotation, as previously determined.^[14, 15]

15 **Antifungal activity evaluation**

16
17 *Table 1* shows that derivative **2**, **5**, and **6** exhibit significant antifungal activities.
18 Our results indicate that compound **2** exhibits a substantial antifungal effect, specifically of
19 73.3% against *B. cinerea*. Compound **5** demonstrates significant antifungal activity of
20 77.8% and 94.1% against *A. flavus* and *A. parasiticus*, respectively. It also inhibits the
21 growth of other pathogens, namely *P. expansum* (73.2%) and *P. verrucosum* (80.9%).
22 Additionally, compound **5** exhibits antifungal activity of 66.7% against *B. cinerea*.
23 Compound **6** demonstrates noteworthy overall antifungal efficacy, with inhibitions of
24 71.4%, 63.9%, 73.5%, and 82.1% against *A. niger*, *A. flavus*, *A. parasiticus*, and *A.*
25 *ochraceus*, respectively. However, it is important to note that none of the synthesized

1 derivatives exhibit significant antifungal activity against *A. alternata*, *A. tenuissima*, or
 2 *Fusarium oxysporum*.

3

4 **Table 1.** Percent antifungal activity.

Fungi	Compound					
	2	3	4	5	6	7
<i>Aspergillus ssp.</i>						
<i>A. niger</i>	35.71	46.43	32.14	39.29	71.43	53.57
<i>A. flavus</i>	16.67	27.78	25.00	77.78	63.89	22.22
<i>A. parasiticus</i>	20.59	29.41	26.47	94.12	73.53	26.47
<i>A. ochraceus</i>	32.14	32.14	32.14	50.00	82.14	28.57
<i>Penicillium ssp.</i>						
<i>P. expansum</i>	24.39	31.71	41.46	73.17	21.95	46.34
<i>P. verrucosum</i>	33.33	30.95	35.71	80.95	38.10	40.48
<i>Alternaria ssp.</i>						
<i>A. alternata</i>	33.33	29.63	22.22	37.04	14.81	33.33
<i>A. tenuissima</i>	34.62	34.62	30.77	38.46	26.92	34.62
<i>Botrytis ssp.</i>						
<i>B. cinerea</i>	73.33	53.33	46.67	66.67	53.33	60.00
<i>Fusarium ssp.</i>						
<i>F. oxysporum</i>	25.71	22.86	28.57	31.43	20.00	34.29

5

6

7

8 **Antibacterial activity evaluation**

9 The results of the antibacterial assays conducted on compounds **2** to **7** revealed that the
 10 MICs values were higher than 50 $\mu\text{g/mL}$ (*Table 2*). These results indicate that the assayed
 11 compounds were inactive against the selected bacteria.

12

13

14

1 **Table 2.** Antibacterial activity.

Microorganisms	Compound MIC ($\mu\text{g/mL}$)						CTX	IPM
	2	3	4	5	6	7		
Gram (+)								
<i>Staphylococcus aureus</i> methicillin-sensitive ATCC 25923	>50	>50	>50	>50	>50	>50	0.5	0.5
<i>Staphylococcus aureus</i> methicillin-resistant ATCC 43300	>50	>50	>50	>50	>50	>50	0.5	0.5
Gram (-)								
<i>Escherichia coli</i> ATCC 25922	>50	>50	>50	>50	>50	>50	0.25	0.5
<i>Escherichia coli</i> 11089	>50	>50	>50	>50	>50	>50	0.25	0.5

2 **Abbreviations:** CTX, cefotaxime; IPM, imipenem.

3

4

5

Accepted Manuscript


1 **Computational studies**

2 **Drug-likeness profile**

3 The compounds underwent a comprehensive assessment for their drug likeness
4 profile, as detailed in *Table S1*. In terms of solubility, as determined by LogS,
5 compounds **2** to **7** are categorized as moderately to poorly soluble in water (-
6 $5.601 < \text{LogS} < -4.145$), whereas **cbz** is anticipated to be soluble in water ($\text{LogS} \approx -1.829$).
7 Furthermore, the partition coefficient LogP values range from 3.654 to 4.501 for
8 compounds **2** to **7**, whereas **cbz** is predicted to have a $\text{LogP} \approx 1.391$. This high LogP
9 suggests the hydrophobic nature of **2** to **7**, facilitating their solubility in lipids.^[16] These
10 findings, in conjunction with other physicochemical descriptors, indicate significant oral
11 bioavailability. Notably, none of the derivatives violated drug-likeness rules and all
12 adhered to the Rule of Five (RO5). For a rapid overview of their drug-likeness, a
13 bioavailability radar plot is presented in *Figure 1*, showcasing six different
14 physicochemical properties: lipophilicity, size, polarity, solubility, flexibility, and
15 saturation.^[17]

16

17




22 **Figure 1.** Bioavailability radar plot. Six physicochemical properties are taken into
23 account (i.e. LIPOphilicity, SIZE, POLARity, INSOLUbility, INSATUration, and
24 FLEXibility. Physicochemical range on each axis is depicted as a pink area in which the
25 radar plot of the target compound has to fall entirely to be considered drug-like.

1 Pharmacokinetics analysis

2 The pharmacokinetic data, as listed in *Table S2*, indicate that all compounds
3 exhibit high levels of passive gastrointestinal absorption (GIA) and passive permeation
4 across the blood-brain barrier (BBB). Furthermore, these compounds are predicted to be
5 unaffected by active efflux P-gp proteins (PGP⁻). These critical ADME parameters,
6 namely GIA, BBB permeation, and P-gp binding, are depicted in a boiled-egg diagram
7 in *Figure 2*.^[17] Pharmacokinetic analysis suggests that compounds **2** to **7** could serve as
8 substrates for CYP-mediated metabolic biotransformations.^[18]

9
10



11
12
13
14

Figure 2. Boiled-egg diagram.

1 Toxicological Risks

2 We assessed the potential toxicity of compounds **2** to **7** using machine-learning
3 models designed to predict various toxicity endpoints.^[19] The corresponding data is
4 presented in *Table S3*.

5 Compound **2** is estimated to have an LD₅₀ of 2500 mg/kg and falls into acute
6 oral toxicity class 5, as predicted. This compound is expected to exhibit inactivity across
7 twelve toxicological pathways, four toxicological endpoints, and hepatotoxicity.
8 However, Opioid receptor mu is identified as a potential toxicity target. Compounds **3**,
9 **4**, and **5** are predicted to have LD₅₀ values of 541 mg/kg, 780 mg/kg, and 800 mg/kg,
10 respectively, categorizing them as acute oral toxicity class 4. These compounds are also
11 anticipated to be inactive across the twelve toxicological pathways and hepatotoxicity.
12 No binding to any of the 15 toxicity targets^[19] is anticipated for compounds **3** to **7**.
13 Compounds **6** and **7** are expected to fall into toxicity class 4, each with an LD₅₀ value of
14 940 mg/kg. They are predicted to exhibit immunotoxicity with high confidence scores
15 of 0.67 and 0.72, respectively, and no binding to any of the 15 toxicity targets is
16 foreseen for these compounds. Lastly, reference compound **cbz** is predicted active for
17 hepatotoxicity and mutagenicity. This compound is also predicted as active for nuclear
18 receptor signaling and stress response pathways. These findings align perfectly with
19 prior research, which has demonstrated that **cbz** can lead to embryotoxicity, apoptosis,
20 teratogenicity, infertility, hepatocellular dysfunction, endocrine-disrupting effects,
21 disruption of haematological functions, mitotic spindle abnormalities, mutagenicity, and
22 aneugenicity effects. These effects have been documented in both acute and delayed
23 experiments.^[20]

1 In summary, our research indicates that none of the NSTHIQ derivatives display
2 hepatotoxicity. Additionally, compounds **2**, **3**, **4**, and **5** emerge as potential safe
3 derivatives based on our results. These compounds exhibited inactivity in various
4 nuclear receptor signalling and stress response pathways. Conversely, derivatives **6** and
5 **7** are predicted to exhibit immunotoxicity, and therefore, we do not categorize them as
6 safe options.

7

8 **Reactivity descriptors**

9 The reactivity of a substrate stands as the foremost determinant in enzyme-
10 mediated biotransformations. Consequently, one can formulate atomic and molecular
11 reactivity indices through the utilization of electronic descriptors derived from quantum
12 chemistry methodologies. To achieve this, optimized geometries at the IEFPCM-
13 B3LYP-GD3BJ/6-311+G(2d,p) level of theory, were scrutinized with a focus on
14 characterizing them as minima (i.e. no imaginary frequencies found) through frequency
15 calculations. The optimized coordinates at the local conformational minimum are
16 provided in *Table S4*, and selected energy values related to the local minimum
17 conformation have been compiled in *Table S5*.

18 Given that valence electrons move through reactive orbitals during chemical
19 reactions, Fukui's frontier orbital theory highlights the significance of the highest
20 occupied molecular orbital (HOMO) and the lowest unoccupied molecular orbital
21 (LUMO) in comprehending chemical reactivity.^[21] The global chemical reactivity
22 properties, derived from a topological analysis of Fukui functions (TAFF), have been
23 documented in *Table 3* for reference.^[22]

24

25

1 **Table 3.** Global chemical reactivity.

Index ^[a]	Compound						
	2	3	4	5	6	7	cbz
HOMO energy	-0.253	-0.253	-0.253	-0.254	-0.229	-0.239	-0.228
LUMO energy	-0.049	-0.026	-0.042	-0.049	-0.049	-0.049	-0.034
GAP	0.204	0.228	0.211	0.205	0.180	0.190	0.194
Ionization potential	0.253	0.253	0.253	0.254	0.229	0.239	0.228
Electroaffinity	0.049	0.026	0.042	0.049	0.049	0.049	0.034
Chemical potential	-0.151	-0.140	-0.148	-0.152	-0.139	-0.144	-0.131
Global Hardness	0.102	0.114	0.106	0.102	0.090	0.095	0.097
Global Softness	4.894	4.395	4.739	4.879	5.559	5.272	5.145
Electronegativity	0.151	0.140	0.148	0.152	0.139	0.144	0.131
Electrophilicity Index	0.112	0.086	0.103	0.112	0.108	0.110	0.088
w- Electron Donator	0.200	0.170	0.190	0.201	0.188	0.193	0.166
w+ Electron Acceptor	0.049	0.030	0.043	0.049	0.049	0.049	0.035
Electrophilicity Net	0.249	0.200	0.233	0.250	0.238	0.243	0.200

2 [a] in atomic units (a.u.)

3

4

5


6 The energy gap between the HOMO and LUMO provides insights into diverse
7 charge-transfer possibilities within the molecules under consideration. Specifically, for
8 molecules **2** to **7**, the determined energy gap values were as follows: 0.204, 0.228,
9 0.211, 0.205, 0.180, and 0.190 atomic units, respectively (*Table 3*). Based on these
10 outcomes, it is evident that compounds **3** and **6** exhibit the highest and lowest stability,
11 respectively. In particular, the analysis using TAFF suggests that compound **6** possesses
12 the smallest HOMO-LUMO gap, presumably indicating a correlation with the observed
13 biological activity. On another hand, global softness, denoted as the reciprocal of global
14 hardness, serves as a metric for assessing polarizability, and the information gleaned
15 from the total molecular softness is particularly well-suited for the analysis of inter- and
16 intramolecular reactivity.^[23] Notably, in *Table 3*, we observe that Compound **6** exhibits
17 the highest global softness among the compounds examined. Furthermore, as depicted
18 in *Table 3*, the active compounds, **5** and **6**, have higher net electrophilicity. Net
19 electrophilicity measures a species' ability to acquire electrons about its capacity to

1 donate them.^[24] It is worth highlighting that numerous chemical toxicants and their
2 active metabolites are electrophilic, thereby causing cellular harm by forming covalent
3 bonds with nucleophilic targets on biological macromolecules.^[25] In summary, our
4 results suggest that Compounds **2**, **5**, **6**, and **7** possess global softness and net
5 electrophilicity levels comparable to, or higher than, the reference compound **cbz**.

6 Although global indices can offer valuable insights into reactivity across an
7 entire system, we have directed our attention towards local properties aiming to
8 comprehend the factors influencing chemical selectivity.^[26] In *Figure 3*, we present
9 sketches illustrating the Fukui function topology for nucleophilic (f+) and electrophilic
10 (f-) attacks on active compounds **5** and **6**. As expected, the benzylsulphonyl framework
11 acts as an electron-withdrawing group, resulting in more pronounced overall electron
12 withdrawal effects, particularly in the presence of halogen substitution.^[27] In contrast,
13 the tetrahydroisoquinoline scaffold acts as a weaker electron-donating base. This is
14 attributed to the nitrogen atom in tetrahydroisoquinoline, whose electron pair is firmly
15 held due to its delocalization within the π system of the aromatic ring. Furthermore, in
16 our findings, the maxima of the Fukui functions could be linked to the primary sites of
17 metabolic attacks and highly reactive electrophilic oxidants in cytochromes, as
18 extensively discussed elsewhere.^[28,29]

19
20

1



2 **Figure 3.** Electron acceptor isosurfaces (f+) in blue, and electron donor isosurfaces (f-)
3 in red. This applies to both compound **5** (sketches A and C) and compound **6** (sketches
4 B and D). The isosurfaces are depicted with a contour level set at 0.006 atomic units.

5

6

7 **Conclusions**

8 In the present study, we have successfully synthesized six derivatives of
9 NSTHIQ employing an environmentally friendly Preyssler heteropolyacid catalyst.
10 These derivatives were obtained with moderate to good yields, swift reaction times, and
11 mild reaction conditions, all achieved with the assistance of a non-corrosive solid
12 catalyst. Upon in vitro assessment of derivatives **5** and **6**, we uncovered significant
13 antifungal activity against various fungal species, including *Aspergillus spp*, *Penicillium*
14 *spp*, and *Botrytis cinerea*. However, it is worth noting that none of the derivatives
15 exhibited antibacterial activity. Additionally, an ADMET (Absorption, Distribution,
16 Metabolism, Excretion, and Toxicity) analysis indicated the absence of hepatic toxicity

1 in all synthesized derivatives. Moreover, compounds **2**, **3**, **4**, and **5** may be considered as
2 potentially safe derivatives. In contrast, derivatives **6** and **7** are predicted to possess
3 immunotoxicity. To complement these experimental findings, reactivity indices
4 computations were carried out using conceptual Density Functional Theory, which, to a
5 certain extent, substantiated our findings.

6

7 **Experimental Section**

8 **Experimental**

9 Chemicals were purchased from chemical companies such as Aldrich and Fluka
10 and were freshly used after purification by standard procedures (distillation and
11 recrystallization), TLC monitored all the reactions. The yields were calculated from
12 purified compounds. The synthesized products were identified by comparing physical
13 data previously reported.^[30-32] Melting points were determined in sealed capillary tubes
14 and were uncorrected. Room temperature ¹H- (400.1 MHz) and ¹³C- (100.6 MHz) NMR
15 measurements were performed on a Bruker Avance DPX-400 spectrometer. The
16 chemical shift standard was internal tetramethylsilane for ¹H- and ¹³C-NMR. The
17 following abbreviations were used for chemical shift multiplicities spectra: br s=broad
18 singlet, br d=broad doublet, br m=broad multiplet, s=singlet, d=doublet, t=triplet,
19 q=quartet, sep=septet, m=multiplet, ps=pseudo. Experimental ¹H-NMR and ¹³C-NMR
20 signals assignments are accompanied by neural networks predicted chemical shifts
21 spectral data^[13] to guarantee and corroborate unbiased signals assignments. MS was
22 measured by VG Autospec mass spectrometer.

23

24 **Synthesis of Preyssler catalyst**

1 The catalyst was prepared using established methods.^[10,33] To synthesize the
2 potassium salt, we dissolved $\text{Na}_2\text{WO}_4 \cdot 2\text{H}_2\text{O}$ (23.0 g, 0.07 mol) and $\text{Na}_2\text{MoO}_4 \cdot 2\text{H}_2\text{O}$
3 (2.0 g, 0.008 mol) in 20 mL of hot distilled water, employing reflux with continuous
4 stirring. Subsequently, H_3PO_4 (85%, 27 mL, 0.02 mol) was slowly added and the
5 mixture was refluxed for 24 hours. Following this, we introduced HNO_3 (70%, 1 mL)
6 and KCl (10 g, 0.13 mol) into the mixture, and it was stirred. The resulting suspension
7 underwent centrifugation for 15 minutes. The solid obtained was dissolved in 50 mL of
8 hot distilled water and allowed to cool overnight at approximately 4 °C. The resulting
9 $\text{K}_{14}[\text{NaP}_5\text{W}_{29}\text{MoO}_{110}]$ was filtered and vacuum-dried at room temperature to yield
10 Preyssler acid (PwMo). The potassium salt solution was passed through a Dowex®
11 50Wx8 ion-exchange column, and the exchanged solution was subsequently dried in an
12 air column. The solid underwent comprehensive characterization using various
13 techniques, including Fourier transform infrared spectroscopy, diffuse reflectance
14 spectroscopy, X-ray diffraction, scanning electron microscopy, textural analysis (S_{BET})
15 via nitrogen adsorption/desorption, and potentiometric titration. The characterization
16 results confirmed the effective synthesis of Preyssler PwMo, consistent with prior
17 reports.^[33]

19 **Catalytic synthesis of NSTHIQ**

20
21 In our experimental setup, we utilized a round-bottom flask equipped with a
22 condenser. The reactants, specifically *N*-phenyl-ethylsulfonamide (**1**), trioxane, and
23 PwMo, were employed in quantities of 1 mmol, 3 mmol, and 1% mmol, respectively.
24 The *N*-phenyl-ethylsulfonamide (**1**) was obtained from a previous study.^[30]

1 To initiate the reaction, the mixture was dissolved in 2 mL of toluene and stirred
2 at 70 °C for of 30 minutes. Subsequently, an additional 10 mL of solvent was
3 introduced, and the catalyst was separated via filtration, followed by a thorough wash
4 with toluene. The resulting solution underwent desiccation using anhydrous Na₂SO₄ and
5 was then filtered. The solvent was evaporated, yielding the product (compounds **2** to **7**),
6 which was subsequently purified through recrystallization using either acetone or ethyl
7 acetate to attain pure compounds. The structural elucidation of the obtained compounds
8 was carried out using spectroscopic techniques, including ¹H- and ¹³C-NMR, as well as
9 mass spectrometry (MS).

10

11 **Monosporic cultures of microorganisms**

12 In our investigation of antifungal activity, we examined the impact on several
13 fungal species, including four distinct *Aspergillus* species (*A. niger*, *A. flavus*, *A.*
14 *parasiticus*, and *A. ochraceus*), two *Penicillium* species (*P. expansum* and *P.*
15 *verrucosum*), two *Alternaria* species (*A. alternate* and *A. tenuissima*), as well as *Botrytis*
16 *cinerea* and *Fusarium oxysporum*. These fungi were cultivated in tilted tubes on potato
17 dextrose agar (PDA) from Sigma-Aldrich, USA, and were allowed to grow for a period
18 of 5 days at a temperature of 22 °C. Subsequently, they were isolated and purified
19 through monosporic culture in the following manner: Conidia were reconstituted in
20 microtubes containing 1 mL of 0.1% Tween 80 under aseptic conditions, creating a
21 suspension for each tube containing the growing fungi. This suspension was then
22 subjected to vortexing three times for 15 seconds each, and the spore count was
23 determined using a Neubauer chamber. Finally, dilutions of each suspension were
24 prepared, resulting in a final concentration of 1x10⁵ spores/mL for each monosporic
25 culture.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

Assessment of antifungal activity by Growth inhibitory assay

Agar-well diffusion susceptibility test

We assessed the antifungal activity of the NSTHIQ compounds using the agar well diffusion method. In this procedure, 100 μ L suspensions of each studied fungal strain were evenly spread onto Petri dishes with a diameter of 15 cm, pre-filled with potato dextrose agar (PDA), and distributed using a Drigalski spatula within a laminar flow cabinet. For each chemical compound under examination, three plates were employed. In each of these plates, three wells, each measuring 6 mm in diameter, were aseptically created. Subsequently, these wells were filled with 50 μ L of a test compound solution, with different dilutions prepared in triplicate. These compounds were initially dissolved in DMF to achieve final concentrations of 1, 5, and 10 mM/mL. To ensure sterility, the solutions were subsequently filtered using a 0.22 μ m filter. All Petri dishes were then incubated at a temperature of 22 $^{\circ}$ C for 4 days. After this incubation period, we measured the radial growth of the mycelium for each respective microorganism and determined the corresponding inhibition zones' diameters in millimetres (*Table S6*). Concurrently, control experiments were conducted, including negative controls using DMF without any antibiotic and positive controls utilizing carbendazim (**cbz**) dissolved in DMF, a systemic polyvalent fungicide. We repeated each experiment a minimum of three times to ensure consistency. The results were expressed as the percentage of mycelium growth inhibition relative to the carbendazim control, where 100% inhibition represented the level achieved by carbendazim. Compounds were classified as active if the percentage of mycelium growth inhibition, in comparison to carbendazim, exceeded 60%.

1 **Antibacterial activity**

2 Reference strains from the American Type Culture Collection (ATCC) were
3 chosen for this study, encompassing two Gram-positive bacterial strains, methicillin-
4 sensitive *Staphylococcus aureus* ATCC 25923 (MSSA) and methicillin-resistant
5 *Staphylococcus aureus* ATCC 43300 (MRSA), as well as the Gram-negative
6 *Escherichia coli* (EC) strains ATCC 25922 and ATCC 11089. Each strain underwent
7 overnight cultivation in Mueller-Hinton broth. The inoculum concentration employed
8 ranged from 1 to 5×10^5 colony forming units per millilitre (CFU/mL), adhering to the
9 guidelines set forth by the Clinical and Laboratory Standards Institute.^[34] For the
10 determination of Minimal Inhibitory Concentration (MIC) of compounds **2** to **7**, the
11 broth microdilution technique was employed. Stock solutions of each compound in
12 dimethylsulphoxide (DMSO) were prepared and subsequently diluted to create serial
13 twofold dilutions.^[34] These dilutions were then added to the respective culture media to
14 achieve final concentrations spanning from 1 to 100 $\mu\text{g/mL}$. The final concentration of
15 DMSO in the assay did not exceed 1%. As positive controls, the assays included the
16 antimicrobial agents Cefotaxime® (Argentia Pharmaceutica) and Imipinem
17 (Laboratorio NORTHIA Argentina). The microplates, each containing 96 wells,
18 underwent 24-hour incubation at 37 °C, with the effects evaluated using a
19 spectrophotometer, measuring absorbance at 620 nm with the Multiskan FC instrument.
20 Tests were made in triplicate and MIC values are expressed as $\mu\text{g/mL}$.

21

22 **Computational analysis**

23 **Drug-likeness profile**

24 The Rule of Five (RO5), which evaluates a chemical compound's drug-likeness,
25 is based on specific physicochemical parameters. These parameters include a molecular

1 weight (MW) less than 500 Dalton, high lipophilicity assessed by a ClogP value ≤ 5 ,
2 fewer than 5 hydrogen bond donors (HBD), fewer than 10 hydrogen bond acceptors
3 (HBA), and a molar refractivity (MR) within the range of 40-130.^[35] This guideline
4 serves as a general framework to determine whether a chemical compound possesses the
5 requisite chemical and physical attributes for potential oral drug activity in humans.^{[35,}
6 ^{36]} To assess the drug-likeness profile, we employed the SwissADME web tool in
7 conjunction with the ADMETlab website.^[17,37]

8

9 **ADME analysis**

10 The primary causes of drug development failures often stem from unfavourable
11 pharmacokinetics profiles in drug-likeness candidates. Consequently, it is imperative to
12 undertake early evaluations of a compound's potential suitability as a drug to enhance
13 research and development efficiency. Presently, assessing ADME (Absorption,
14 Distribution, Metabolism, and Excretion) characteristics typically entails resource-
15 intensive, time-consuming processes and often necessitates extensive animal
16 experimentation. Consequently, computer-based modelling techniques have emerged as
17 the preferred approach in the initial phases of drug discovery for ADME prediction. To
18 assess the ADME profile, we utilized the SwissADME web tool and the pkCSM
19 server.^[17,38]

20

21 **Toxicological Risks**

22 To predict the toxicological risks associated with selected compounds using
23 structural models, we employed the ProTox-II web server.^[19,39] This tool encompasses
24 molecular similarity, pharmacophores, fragment propensities, and machine-learning
25 models for predicting various toxicity endpoints.^[19,39] For the NSTHIQ derivatives, we

1 computed the following toxicity endpoints: 1) Acute toxicity, including toxicity classes,
2 oral LD50, and predicted accuracy percentage. 2) Organ toxicity, specifically
3 hepatotoxicity. 3) Various toxicological endpoints, encompassing carcinogenicity,
4 immunotoxicity, mutagenicity, and cytotoxicity. 4) Toxicological pathways, divided
5 into nuclear receptor signalling pathways (such as aryl hydrocarbon receptor, androgen
6 receptor, and peroxisome proliferator-activated receptor gamma) and stress-response
7 pathways (including nuclear factor erythroid-derived 2-like 2/antioxidant responsive
8 element, heat shock factor response element, mitochondrial membrane potential,
9 phosphoprotein p53, and ATPase family AAA domain-containing protein 5); and finally
10 5) Toxicity targets, which comprised 15 distinct models.^[19,39,40] Compounds predicted
11 to carry a toxicological risk were categorized as "Active," along with their associated
12 confidence scores for such events. Conversely, compounds devoid of any predicted
13 toxicological risk were classified as "Inactive." Notably, compounds falling into the
14 "Inactive" category are more likely to exhibit effectiveness in subsequent *in vitro* and *in*
15 *vivo* experiments.

16

17 **Density Functional Theory (DFT) calculations**

18 DFT calculations were conducted for all compounds, involving modelling and
19 energy minimization. These calculations were executed using the Gaussian 16 program.
20 ^[41] We employed the B3LYP DFT functional coupled with homogenous 6-311+G(2d,p)
21 Pople-style orbital basis sets.^[42,43] To accurately account for noncovalent and dispersion
22 interactions, we applied Grimme's dispersion with Becke–Johnson damping (GD3BJ)
23 correction.^[44] Additionally, the solvent environment was considered using the integrated
24 effective fragment polarizable continuum model (IEFPCM) with a dielectric constant
25 (ϵ) set at 4.^[45] Following geometry optimization, vibrational frequency analyses were

1 conducted to characterize the stationary points on the potential energy surface and to
2 calculate zero-point energy (ZPE) corrections. Subsequently, the resulting electronic
3 structure underwent topological analysis of the Fukui function (TAFF).^[22] The Fukui
4 function is a fundamental concept within DFT, providing insights into global and local
5 molecular reactivity parameters.^[46] Sites with higher Fukui function values are favoured
6 as reaction sites. Based on Koopmans' theorem, we determined ionization potential (I),
7 electroaffinity (A), chemical potential (μ), global hardness (η), global softness (S),
8 electronegativity (χ), electrophilicity index (ω), electron acceptor index (ω^+), electron
9 donor index (ω^-), and net electrophilicity ($\Delta\omega^\pm$).^[22] These parameters were derived
10 from the highest occupied molecular orbital (HOMO) and the lowest unoccupied
11 molecular orbital (LUMO), applying topological analysis of the Fukui function.^[22]

12

13 **Acknowledgements**

14 G.P.R. and H.A.B. acknowledge funding from National Scientific and Technical
15 Research Council – Argentina (CONICET) under Projects PIP0111 and PIP090CO,
16 respectively. M.E.R.T., V.P., M.A.F.B., B.L., G.E.F., G.P.R., and H.A.B. are researcher
17 from CONICET. This work partially used computational resources from CCAD-UNC,
18 which is part of SNCAD-MinCyT, Argentina.

19

20 **Author Contribution Statement**

21 M.E.R.T., M.A.F.B., F.A.G., J.R.A.D., and B.L. conducted the experiments and
22 analyzed the data, reviewed and edited the manuscript. V.P. and G.P.R prepared
23 compounds, analyzed the data, reviewed and edited the manuscript. G.E.F., G.P.R. and
24 H.A.B. supervision, analyzed the data, reviewed and edited the manuscript, project
25 administration and funding acquisition.

1

2 **Keywords:** ADMET, antibacterial, antifungal, sulfonamide, tetrahydroisoquinolines

3

4 **References**

- 5 [1] S. McGuire, *Adv. Nutr.* **2015**, *6*, 623-624.
- 6 [2] A. Moretti, A. F. Logrieco, A. Susca, *Methods Mol. Biol.* **2017**, *1542*, 3-12.
- 7 [3] A. E. Pohland, *Food Addit. Contam.* **1993**, *10*, 17-28.
- 8 [4] V. S. Brauer, C.P. Rezende, A. M. Pessoni, R.G. De Paula, K.S. Rangappa, S. C.
9 Nayaka, V. K. Gupta, F. Almeida, *Biomolecules* **2019**, *9*, Article 521.
- 10 [5] I. P. Singh, P. Shah, *Expert Opin. Ther.* **2017**, *27*, 17-36.
- 11 [6] C. Zhao, K. P. Rakesh, L. Ravidar, W. Y. Fang, H.L. Qin, *Eur. J. Med. Chem.*
12 **2019**, *162*, 679-734.
- 13 [7] W. M. Whaley, T.R. Govindachari, 'Organic Reactions', John Wiley & Sons,
14 New York, NY, USA, **1951**, Vol. VI, p. 74-144.
- 15 [8] R. Pingaew, S. Prachayasittikul, S. Ruchirawat, V. Prachayasittikul, *Chin. Chem.*
16 *Lett.* **2013**, *24*, 941-944.
- 17 [9] E. X. Aguilera Palacios, V. Palermo, A. G. Sathicq, L.R. Pizzio, G. P. Romanelli,
18 *Catalysts* **2022**, *12*, Article 1155.
- 19 [10] F. F. Bamoharram, M. M. Heravi, M. Roshani, M. Jahangir, A. Gharib, *Appl.*
20 *Catal., A* **2006**, *302*, 42-47.
- 21 [11] M. M. Heravi, Z. Faghihi, *J. Iran. Chem. Soc.* **2014**, *11*, 209-224.
- 22 [12] G. P. Romanelli, D.M. Ruiz, J. C. Autino, H. E. Giaccio, *Mol. Divers.* **2010**, *14*,
23 803-807.
- 24 [13] D. Banfi, L. Patiny, *Chimia* **2008**, *62*, 280-281.
- 25 [14] C. M. Breneman, L.W. Weber, *Can. J. Chem.* **1996**, *74*, 1271-1282.


- 1 [15] A. Vigorito, C. Calabrese, A. Maris, D. Loru, I. Pena, M. E. Sanz, S. Melandri,
2 *Molecules* **2022**, Article 2820.
- 3 [16] J. S. Delaney, *J. Chem. Inf. Comput. Sci.* **2004**, *44*, 1000-1005.
- 4 [17] A. Daina, O. Michielin, V. Zoete, *Sci. Rep.* **2017**, *7*, Article 42717.
- 5 [18] L. Di, *Expert Opin. Drug Metab. Toxicol.* **2014**, *10*, 379-393.
- 6 [19] M. N. Drwal, P. Banerjee, M. Dunkel, M. R. Wettig, R. Preissner, *Nucleic Acids*
7 *Res.* **2014**, *42*, W53-58.
- 8 [20] S. Singh, N. Singh, V. Kumar, S. Datta, A. B. Wani, D. Singh, K. Singh, J.
9 Singh, *Environ. Chem. Lett.* **2016**, *14*, 317-329.
- 10 [21] K. Fukui, *Chemical Reactivity Theory*, Springer Berlin Heidelberg, Berlin,
11 Heidelberg, **1975**, p. 8-9.
- 12 [22] P. Fuentealba, E. Florez, W. Tiznado, *J. Chem. Theory Comput.* **2010**, *6*, 1470-
13 1478.
- 14 [23] P. Geerlings, F. De Proft, W. Langenaeker, *Chem. Rev.* **2003**, *103*, 1793-1874.
- 15 [24] P. K. Chattaraj, A. Chakraborty, S. Giri, *J. Phys. Chem. A* **2009**, *113*, 10068-
16 10074.
- 17 [25] R. M. Lopachin, T. Gavin, A. Decaprio, D. S. Barber, *Chem. Res. Toxicol.* **2012**,
18 *25*, 239-251.
- 19 [26] P. K. Chattaraj, *J. Phys. Chem. A* **2001**, *105*, 511-513.
- 20 [27] I. Chataigner, C. Panel, H. Gérard, S.R. Piettre, *Chem. Commun.* **2007**, *31*, 3288-
21 3290.
- 22 [28] M. E. Beck, *J. Chem. Inf. Model.* **2005**, *45*, 273-282.
- 23 [29] M. Newcomb, R. E. Chandrasena, *Biochem. Biophys. Res. Commun.* **2005**, *338*,
24 394-403.

- 1 [30] O. O. Orazi, R. A. Corral, H. Giaccio, *J. Chem. Soc., Perkin Trans. 1* **1986**, *1*,
2 1977-1982.
- 3 [31] J. L. Jios, G.P. Romanelli, J. C. Autino, H.E. Giaccio, H. Duddeck, M. Wiebcke,
4 *Magn. Reson. Chem.* **2005**, *43*, 1057-1062.
- 5 [32] M. Natsume, S. Kumadaki, K. Kiuchi, *Chem. Pharm. Bull.* **1972**, *20*, 1592-1595.
- 6 [33] D. M. Ruiz, G. P. Romanelli, P. G. Vázquez, J. C. Autino, *Appl. Catal., A* **2010**,
7 *374*, 110-119.
- 8 [34] R. Humphries, A. M. Bobenchik, J. A. Hindler, A. N. Schuetz, *J. Clin.*
9 *Microbiol.* **2021**, *59*, e0021321.
- 10 [35] C. A. Lipinski, F. Lombardo, B. W. Dominy, P. J. Feeney, *Adv. Drug Deliv.*
11 *Rev.* **1997**, *23*, 3-25.
- 12 [36] C. A. Lipinski, *Drug Discov. Today Technol.* **2004**, *1*, 337-341.
- 13 [37] G. Xiong, Z. Wu, J. Yi, L. Fu, Z. Yang, C. Hsieh, M. Yin, X. Zeng, C. Wu, A.
14 Lu, X. Chen, T. Hou, D. Cao, *Nucleic Acids Res.* **2021**, *49*, W5-W14.
- 15 [38] D. E. V. Pires, T. L. Blundell, D. B. Ascher, *J. Med. Chem.* **2015**, *58*, 4066-
16 4072.
- 17 [39] P. Banerjee, A. O. Eckert, A. K. Schrey, R. Preissner, *Nucleic Acids Res.* **2018**,
18 *46*, W257-W263.
- 19 [40] P. Banerjee, F. O. Dehnbostel, R. Preissner, *Front. Chem.* **2018**, *6*, Article 362.
- 20 [41] M. J. Frisch, G. W. Trucks, H. B. Schlegel, G. E. Scuseria, M. A. Robb, J. R.
21 Cheeseman, G. Scalmani, V. Barone, G. A. Petersson, H. Nakatsuji, X. Li, M.
22 Caricato, A. V. Marenich, J. Bloino, B. G. Janesko, R. Gomperts, B. Mennucci,
23 H. P. Hratchian, J. V. Ortiz, A. F. Izmaylov, J. L. Sonnenberg, Williams, F.
24 Ding, F. Lipparini, F. Egidi, J. Goings, B. Peng, A. Petrone, T. Henderson, D.
25 Ranasinghe, V. G. Zakrzewski, J. Gao, N. Rega, G. Zheng, W. Liang, M. Hada,

- 1 M. Ehara, K. Toyota, R. Fukuda, J. Hasegawa, M. Ishida, T. Nakajima, Y.
2 Honda, O. Kitao, H. Nakai, T. Vreven, K. Throssell, J.A. Montgomery Jr., J. E.
3 Peralta, F. Ogliaro, M. J. Bearpark, J. J. Heyd, E. N. Brothers, K. N. Kudin, V.
4 N. Staroverov, T. A. Keith, R. Kobayashi, J. Normand, K. Raghavachari, A. P.
5 Rendell, J. C. Burant, S. S. Iyengar, J. Tomasi, M. Cossi, J. M. Millam, M.
6 Klene, C. Adamo, R. Cammi, J. W. Ochterski, R. L. Martin, K. Morokuma, O.
7 Farkas, J. B. Foresman, D. J. Fox, Gaussian 16 Rev. C.01, Programm for
8 electronic structure modeling, Gaussian, Inc., Wallingford CT, **2016**.
- 9 [42] A. D. Becke, *J. Chem. Phys.* **1993**, *98*, 5648-5652.
- 10 [43] W. J. Hehre, R. Ditchfield, J. A. Pople, *J. Chem. Phys.* **1972**, *56*, 2257-2261.
- 11 [44] H. Schroder, A. Creon, T. Schwabe, *J. Chem. Theory Comput.* **2015**, *11*, 3163-
12 3170.
- 13 [45] P. Bandyopadhyay, M. S. Gordon, B. Mennucci, J. Tomasi, *J. Chem. Phys.*
14 **2002**, *116*, 5023-5032.
- 15 [46] R. G. Parr, W. Yang, *J. Am. Chem. Soc.* **1984**, *106*, 4049-4050.
- 16

1 Graphical Abstract

2



six examples – antifungal and antibacterial assessment – admet – dft

3

4

5

6 Twitter Text

7 @noticiasUNSL

8 @fqbf_unsl

9 @ConicetSanLuis

10 @CINDECA

11 @exatcas_unlp

12 @CONICETLaPlata

13